Evidence map›Paper›PMID 31852519›Full record

ArticleStem cell research & therapy2019

Combination therapies enhance immunoregulatory properties of MIAMI cells.

Fiorella Rossi, Hunter Noren, Leonor Sarria, Paul C Schiller, Lubov Nathanson, Vladimir Beljanski

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Frontiers in cell and developmental biology · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Dual Role of Autophagy in Regulation of Mesenchymal Stem Cell Senescence.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fiorella RossiCell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, Davie, FL, 33328, USA.
Hunter NorenCell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, Davie, FL, 33328, USA.
Leonor SarriaInstitute for Neuroimmune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, FL, USA.
Paul C SchillerDepartment of Orthopaedics, University of Miami Miller School of Medicine, Miami, FL, USA.
Lubov NathansonInstitute for Neuroimmune Medicine, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, FL, USA.
Vladimir BeljanskiCell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, 3200 South University Drive, Fort Lauderdale, Davie, FL, 33328, USA. vbeljanski@nova.edu.ORCID 0000-0002-2005-1628
Nova Southeastern University · USUniversity of Miami · US

Funding

Modulation of therapeutic cells exosome content by autophagyR15GM128189 · NIGMS · NOVA SOUTHEASTERN UNIVERSITY · PI BELJANSKI, VLADIMIR · 2018 to 2020
$527k
Foundation for the National Institutes of Health 1R15GM128189-01NIGMS NIH HHS R15 GM128189
6 · The paper itself

Abstract

backgroundMesenchymal stromal cells (MSCs), adult stromal cells most commonly isolated from bone marrow (BM), are being increasingly utilized in various therapeutic applications including tissue repair via immunomodulation, which is recognized as one of their most relevant mechanism of action. The promise of MSC-based therapies is somewhat hindered by their apparent modest clinical benefits, highlighting the need for approaches that would increase the efficacy of such therapies. Manipulation of cellular stress-response mechanism(s) such as autophagy, a catabolic stress-response mechanism, with small molecules prior to or during MSC injection could improve MSCs' therapeutic efficacy. Unfortunately, limited information exists on how manipulation of autophagy affects MSCs' response to inflammation and subsequent immunoregulatory properties.

methodsIn this study, we exposed BM-MSC precursor cells, "marrow-isolated adult multilineage inducible" (MIAMI) cells, to autophagy modulators tamoxifen (TX) or chloroquine (CQ), together with IFN-γ. Exposed cells then underwent RNA sequencing (RNAseq) to determine the effects of TX or CQ co-treatments on cellular response to IFN-γ at a molecular level. Furthermore, we evaluated their immunoregulatory capacity using activated CD4+ T cells by analyzing T cell activation marker CD25 and the percentage of proliferating T cells after co-culturing the cells with MIAMI cells treated or not with TX or CQ.

resultsRNAseq data indicate that the co-treatments alter both mRNA and protein levels of key genes responsible for MSCs' immune-regulatory properties. Interestingly, TX and CQ also altered some of the microRNAs targeting such key genes. In addition, while IFN-γ treatment alone increased the surface expression of PD-L1 and secretion of IDO, this increase was further enhanced with TX. An improvement in MIAMI cells' ability to decrease the activation and proliferation of T cells was also observed with TX, and to a lesser extent, CQ co-treatments.

conclusionAltogether, this work suggests that both TX and CQ have a potential to enhance MIAMI cells' immunoregulatory properties. However, this enhancement is more pronounced with TX co-treatment.

Indexed as

AutophagyB7-H1 AntigenCD4-Positive T-LymphocytesCell ProliferationChloroquineCoculture TechniquesGene ExpressionHumansIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaInterleukin-6Leukocytes, MononuclearLymphocyte ActivationMesenchymal Stem CellsMicroRNAsTamoxifenB7-H1 AntigenCD274 protein, humanChloroquineIndoleamine-Pyrrole 2,3,-DioxygenaseInterferon-gammaInterleukin-6MicroRNAsTamoxifenAutophagyChloroquineCombination therapiesIDOImmunoregulationMesenchymal stromal cellsPD-L1Tamoxifen

Identifiers

PMID31852519
PMCPMC6921447
OpenAlexW2996723621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.